Perfil inmunohistoquímico de los tumores de células renales / Immunohistochemical profile of renal cell tumours

CONTEXTO: El cáncer de riñón se encuentra entre los 10 cánceres más frecuentes a nivel mundial: cada año se diagnostican alrededor de 270.000 casos y 116.000 personas mueren a causa de la enfermedad. Aproximadamente el 90% de todas las neoplasias sólidas de riñón son carcinomas de células renales. La incidencia en Colombia es de aproximadamente 500-1.000 casos por año. OBJETIVO: Caracterizar a través del uso de marcadores de inmunohistoquímica los diferentes tumores de células renales que se han diagnosticado en el Laboratorio de Patología del Hospital San José (HSJ) y el Hospital Universitario Infantil de San José (HUISJ) de Bogotá. MATERIALES Y MÉTODOS: Se realizó una revisión retrospectiva de las láminas de hematoxilina y eosina y de inmunohistoquímica de todos los carcinomas de células renales diagnosticados en mujeres y hombres mayores de 18 años, en el Laboratorio de Patología del HSJ y el HUISJ de Bogotá desde enero de 2014 hasta diciembre de 2016. Se usaron los anticuerpos: CAIX (anhidrasa carbónica), RCC (marcador del carcinoma de células renales), vimentina, CD10, CK7, TFE3 (factor de transcripción de unión al potenciador IGHM 3), CD117, CD15, CK20, cadherina y PAX8. Se reportaron frecuencias absolutas y relativas de los distintos marcadores mediante análisis univariados y bivariados con una prueba de chi cuadrado. RESULTADOS: Comparando la expresión de los marcadores estadísticamente significativos, resultó un inmunoperfil para el carcinoma de células claras (CRCC) versus el RCC cromófobo (ChRCC) así: CRCC marcadores positivos: CAIX, vimentina, CD15, CD10, cadherina y marcadores negativos: CK7, CD117; ChRCC marcadores positivos: CK7, CD117, CD10, cadherina y marcadores negativos: CAIX, vimentina, CD15. El marcador PAX8 fue positivo o negativo en ambos tumores. CONCLUSIÓN: Cinco marcadores demostraron utilidad y validez para diferenciar entre los subtipos histológicos CRCC y ChRCC. Proponemos la combinación de los marcadores (CAIX, CK7, vimentina, CD15 y CD117) para el diagnóstico diferencial entre CRCC versus ChRCC

CONTEXT: Kidney cancer is among the 10 most frequent cancers in the world, each year about 270,000 cases are diagnosed and 116,000 people die from the disease. Approximately 90% of all solid kidney neoplasms are renal cell carcinomas. The incidence in Colombia is approximately 500-1000 cases per year. OBJECTIVE: To characterize through the use of immunohistochemical markers the different renal cell tumours diagnosed in the pathology laboratory of the San José Hospital (HSJ) and the University Infantil Hospital of San José (HUISJ) in Bogotá. MATERIALS AND METHODS: A retrospective review was performed of the Hematoxylin and eosin and immunohistochemistry slides of all renal cell carcinomas diagnosed in women and men over 18 years in the pathology laboratory of the HSJ and the HUISJ from Bogotá from January 2014 to December 2016. The antibodies used were: CAIX (carbonic anhydrase), RCC (renal cell carcinoma marker), vimentin, CD10, CK7, TFE3 (transcription factor binding to IGHM enhancer 3), CD117, CD15, CK20, cadherin and PAX8. Absolute and relative frequencies of the different markers were reported through univariate and bivariate analyses with a chi-square test. RESULTS: Comparing the expression of statistically significant markers, an immunoprofile resulted for clear cell carcinoma (CRCC) versus RCC chromophobe (ChRCC) as follows: CRCC positive markers: CAIX, vimentin, CD15, CD10, cadherin and negative markers: CK7, CD117; ChRCC positive markers: CK7, CD117, CD10, cadherin and CAIX negative markers: vimentin, CD15. The PAX8 marker was positive or negative in both tumors. CONCLUSIONS: Five markers demonstrated utility and validity to differentiate between histological subtypes of CRCC and ChRCC. We propose the combination of markers (CAIX, CK7, vimentin, CD15 and CD117) for the differential diagnosis between CRCC versus ChRCC

[Immunohistochemical profile of renal cell tumours]. / Perfil inmunohistoquímico de los tumores de células renales.

CONTEXT: Kidney cancer is among the 10 most frequent cancers in the world, each year about 270,000 cases are diagnosed and 116,000 people die from the disease. Approximately 90% of all solid kidney neoplasms are renal cell carcinomas. The incidence in Colombia is approximately 500-1000 cases per year. OBJECTIVE: To characterize through the use of immunohistochemical markers the different renal cell tumours diagnosed in the pathology laboratory of the San José Hospital (HSJ) and the University Infantil Hospital of San José (HUISJ) in Bogotá. MATERIALS AND METHODS: A retrospective review was performed of the Hematoxylin and eosin and immunohistochemistry slides of all renal cell carcinomas diagnosed in women and men over 18 years in the pathology laboratory of the HSJ and the HUISJ from Bogotá from January 2014 to December 2016. The antibodies used were: CAIX (carbonic anhydrase), RCC (renal cell carcinoma marker), vimentin, CD10, CK7, TFE3 (transcription factor binding to IGHM enhancer 3), CD117, CD15, CK20, cadherin and PAX8. Absolute and relative frequencies of the different markers were reported through univariate and bivariate analyses with a chi-square test. RESULTS: Comparing the expression of statistically significant markers, an immunoprofile resulted for clear cell carcinoma (CRCC) versus RCC chromophobe (ChRCC) as follows: CRCC positive markers: CAIX, vimentin, CD15, CD10, cadherin and negative markers: CK7, CD117; ChRCC positive markers: CK7, CD117, CD10, cadherin and CAIX negative markers: vimentin, CD15. The PAX8 marker was positive or negative in both tumors. CONCLUSION: Five markers demonstrated utility and validity to differentiate between histological subtypes of CRCC and ChRCC. We propose the combination of markers (CAIX, CK7, vimentin, CD15 and CD117) for the differential diagnosis between CRCC versus ChRCC.